Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Wen Wee Ma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5899-4034; OpenAlex author ID A5025469479. Sources: ClinicalTrials.gov.

Their work

Papers
28 (first author 1, last author 5)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
2
Collaborators
117
Papers, trials and grants by year

2009: 1 trial · 2010: none · 2011: none · 2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper, 1 trial · 2016: 4 papers · 2017: 1 paper · 2018: 2 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 5 papers

Papers 28

  1. Microfluidic Organoid Cultures Derived from Pancreatic Cancer Biopsies for Personalized Testing of Chemotherapy and Immunotherapy. Co-author DOI 10.1002/advs.202303088↗
  2. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. Co-author DOI 10.1016/j.drup.2024.101064↗
  3. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors … Co-author DOI 10.1111/bph.16289↗
  4. Dual-Hit Strategy for Therapeutic Targeting of Pancreatic Cancer in Patient-Derived Xenograft Tumors. Co-author DOI 10.1158/1078-0432.ccr-23-0131↗
  5. Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers16101861↗
  6. Efficacy of Immune Checkpoint Inhibition and Cytotoxic Chemotherapy in Mismatch Repair-Deficient and Microsatellite Instability-High Pancreatic Cancer: Mayo Cl… Co-author DOI 10.1200/po.22.00706↗
  7. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-021-10991-2↗
  8. FDG-PET Predicts Neoadjuvant Therapy Response and Survival in Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.6004/jnccn.2022.7041↗
  9. The role of microbiome in pancreatic cancer. Last author DOI 10.1007/s10555-021-09982-2↗
  10. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation. Co-author DOI 10.1124/jpet.120.000412↗
  11. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/coc.0000000000000708↗
  12. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1634/theoncologist.2020-0086↗
  13. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. Co-author DOI 10.1097/coc.0000000000000492↗
  14. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model. Co-author DOI 10.1158/1535-7163.mct-18-0354↗
  15. A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve… Co-author DOI 10.1097/coc.0000000000000260↗
  16. The Management of Older Adults with Pancreatic Adenocarcinoma. Co-author DOI 10.3390/geriatrics3040085↗
  17. A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Co-author DOI 10.1007/s00280-017-3375-9↗
  18. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  19. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2016.185↗
  20. Tumor-Priming Smoothened Inhibitor Enhances Deposition and Efficacy of Cytotoxic Nanoparticles in a Pancreatic Cancer Model. Co-author DOI 10.1158/1535-7163.mct-15-0602↗
  21. Targeting stromal microenvironment in pancreatic ductal adenocarcinoma: controversies and promises. Last author DOI 10.21037/jgo.2016.03.03↗
  22. Novel adjuvant therapies for pancreatic adenocarcinoma. First author DOI 10.3978/j.issn.2078-6891.2015.031↗
  23. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  24. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Co-author DOI 10.1056/nejmoa1304369↗
  25. The winning formulation: the development of paclitaxel in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-1356↗
  26. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with soli… Co-author DOI 10.1158/1078-0432.ccr-11-2813↗
  27. Treatment of locally advanced unresectable pancreatic cancer: a 10-year experience. Co-author DOI 10.3978/j.issn.2078-6891.2012.029↗
  28. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗

Trials 3

  1. Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pan… Principal investigator NCT02048943↗
  2. Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydroch… Principal investigator NCT00981162↗
  3. Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Principal investigator NCT02575508↗

Closest collaborators

The 25 strongest of 117 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Robert M. Straubinger · 7 shared papers, 2016–2024 · strength 1.06
  2. Robert R. McWilliams · 7 shared papers, 2020–2024 · strength 0.93
  3. Qingxiang Lin · 4 shared papers, 2021–2024 · strength 0.79
  4. Tista Roy Chaudhuri · 4 shared papers, 2016–2024 · strength 0.70
  5. Tanios Bekaii‐Saab · 5 shared papers, 2020–2024 · strength 0.69
  6. Amit Mahipal · 5 shared papers, 2020–2024 · strength 0.67
  7. Jun Qu · 2 shared papers, 2024 · strength 0.45
  8. Thorvardur Ragnar Halfdanarson · 3 shared papers, 2022–2024 · strength 0.41
  9. Hao Xie · 4 shared papers, 2018–2020 · strength 0.40
  10. Alexander Revzin · 2 shared papers, 2024 · strength 0.35
  11. Daheui Choi · 2 shared papers, 2024 · strength 0.35
  12. Mark Joseph Truty · 3 shared papers, 2020–2022 · strength 0.34
  13. Aakash P. Desai · 2 shared papers, 2023–2024 · strength 0.34
  14. Hani M. Babiker · 2 shared papers, 2023–2024 · strength 0.34
  15. Joleen Marie Hubbard · 3 shared papers, 2018–2020 · strength 0.32
  16. John R. Ogden · 3 shared papers, 2018–2020 · strength 0.32
  17. Alex A. Adjei · 3 shared papers, 2012–2024 · strength 0.27
  18. Nguyen H. Tran · 2 shared papers, 2021–2022 · strength 0.26
  19. Amro M. Abdelrahman · 2 shared papers, 2022 · strength 0.24
  20. Jennifer A. Yonkus · 2 shared papers, 2022 · strength 0.24
  21. Christopher Leigh Hallemeier · 2 shared papers, 2022 · strength 0.24
  22. Sean Patrick Cleary · 2 shared papers, 2022 · strength 0.24
  23. Travis Edward Grotz · 2 shared papers, 2022 · strength 0.24
  24. Rondell Patrell Graham · 2 shared papers, 2022 · strength 0.24
  25. Roberto Alva‐Ruiz · 2 shared papers, 2022 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.